Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer and Oxford Genome Sciences form breast cancer marker pact:

This article was originally published in Clinica

Executive Summary

Bayer HealthCare has teamed up with the UK proteomics technology company, Oxford Genome Sciences (OGeS), to evaluate new biomarkers for breast cancer. OGeS will assess the candidate biomarkers - previously identified by Bayer - that may have important applications in the diagnosis and prognosis of the disease. The evaluation will be performed using OGeS' proteomics platform, in conjunction with its Oxford Genome Anatomy Project (OGAP), which is claimed to be the "world's largest proteomics database". Under the agreement, OGeS will receive programme funding from Bayer, which will also make performance-related payments on the achievement of certain milestones.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel